Autoimmune Gastrointestinal Dysmotility Market Report 2026

The autoimmune gastrointestinal dysmotility market size has grown strongly in recent years. It will grow from $1.82 billion in 2025 to $1.92 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to autoimmune disease diagnosis growth, gastroparesis prevalence, hospital gastroenterology expansion, immunosuppressive drug usage, rare disease awareness.

The autoimmune gastrointestinal dysmotility market size is expected to see strong growth in the next few years. It will grow to $2.63 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to early diagnostic improvements, personalized treatment approaches, long-term care demand, home-based nutrition therapy, autoimmune research expansion. Major trends in the forecast period include increased recognition of rare gastrointestinal disorders, growth in immunosuppressive treatment use, expansion of nutritional and dietary management, rising adoption of multidisciplinary care approaches, focus on long-term symptom management.

The growing number of clinical trials is expected to drive the expansion of the autoimmune gastrointestinal dysmotility market in the coming years. Clinical trials are research studies designed to assess the safety, efficacy, and optimal use of medical interventions - including drugs, biologics, devices, and treatment protocols - in human participants, with the goal of advancing medical knowledge and improving patient care. This increase in clinical trials is largely driven by expanded regulatory requirements for trial registration, rising investment in pharmaceutical research and development, and the accelerating pace of innovation in novel therapeutic approaches such as immunotherapies and biologics for autoimmune conditions affecting gastrointestinal motility. Clinical trials for autoimmune gastrointestinal dysmotility play a key role in advancing treatment options by systematically evaluating new immunosuppressive therapies, prokinetic agents, and biologics, identifying optimal treatment protocols, and establishing evidence-based strategies that support regulatory approval and clinical adoption of therapies targeting autoimmune-mediated gastrointestinal dysfunction. For example, in November 2025, ClinicalTrials.gov, a US-based clinical trials registry managed by the National Institutes of Health, reported that the total number of registered clinical studies reached 477,203 at the end of 2023 (including 437,493 cumulative and 39,710 new registrations) and increased to 520,877 at the end of 2024 (comprising 477,203 cumulative and 43,674 new registrations), reflecting a 9.1% year-on-year growth in total registered studies. Consequently, the rising number of clinical trials is fueling the growth of the autoimmune gastrointestinal dysmotility market.

The increasing prevalence of autoimmune disorders is expected to drive the growth of the autoimmune gastrointestinal dysmotility market in the coming years. Autoimmune diseases occur when the body’s immune system mistakenly attacks its own healthy cells, tissues, or organs instead of defending against infections and foreign substances. This rise in autoimmune disorders is primarily attributed to a combination of genetic susceptibility and environmental triggers, which together disrupt immune regulation and increase the likelihood of the immune system targeting the body’s own tissues. Autoimmune gastrointestinal dysmotility aids in identifying and managing underlying autoimmune conditions by detecting immune-mediated damage to the enteric nervous system, linking gastrointestinal symptoms to systemic autoimmune activity. For example, in October 2024, a comprehensive review published in Signal Transduction and Targeted Therapy, a journal by Nature, reported that approximately 8.4 million people worldwide suffer from rheumatoid arthritis, with incidence rates increasing by 2-3% annually; using a Markov model, the affected population is projected to reach 13.5-17.4 million by 2040. Consequently, the rising prevalence of autoimmune disorders is fueling the expansion of the autoimmune gastrointestinal dysmotility market.

The growing emphasis on personalized medicine is expected to drive the expansion of the autoimmune gastrointestinal dysmotility market in the coming years. Personalized medicine is a medical approach that customizes treatment and prevention strategies according to an individual’s unique genetic profile, lifestyle, and environment. This trend is largely fueled by advancements in genomics, which allow for the precise identification of genetic variations and enable tailored therapies. Personalized medicine supports the management of autoimmune gastrointestinal dysmotility by customizing treatments based on a patient’s genetic makeup and specific disease characteristics, improving therapeutic effectiveness and reducing side effects, thereby providing more targeted solutions for complex gastrointestinal disorders. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a notable increase from 12 approvals in 2022. Consequently, the rising focus on personalized medicine is fueling the growth of the autoimmune gastrointestinal dysmotility market.

Major companies operating in the autoimmune gastrointestinal dysmotility market are AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Rose Pharma LLC, Parvus Therapeutics Inc., CinDome Pharma Inc., Neurogastrx Inc., Renexxion LLC, ISOThrive Inc., Ambrose Healthcare Inc., AnTolRx Inc., Enteralia Bioscience S.r.l., Immunic Inc., Mozart Therapeutics Inc.

North America was the largest region in the autoimmune gastrointestinal dysmotility market in 2025. The regions covered in the autoimmune gastrointestinal dysmotility market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the autoimmune gastrointestinal dysmotility market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the autoimmune gastrointestinal dysmotility market by increasing the cost of imported immunosuppressive drugs, prokinetic agents, and nutritional therapy components. These impacts have been most pronounced in medication and dietary management segments, particularly in north america and europe where treatment inputs are globally sourced. Asia-pacific markets have faced cost pressures. However, tariffs have supported localized manufacturing of supportive gastrointestinal therapies.

The autoimmune gastrointestinal dysmotility market research report is one of a series of new reports that provides autoimmune gastrointestinal dysmotility market statistics, including autoimmune gastrointestinal dysmotility industry global market size, regional shares, competitors with a autoimmune gastrointestinal dysmotility market share, detailed autoimmune gastrointestinal dysmotility market segments, market trends and opportunities, and any further data you may need to thrive in the autoimmune gastrointestinal dysmotility industry. This autoimmune gastrointestinal dysmotility market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Autoimmune gastrointestinal dysmotility (AGID) is a rare condition in which the immune system attacks the nerves that control digestive tract movement. This results in slowed or abnormal motility, leading to symptoms such as nausea, bloating, constipation, or intestinal blockage. AGID is often linked to other autoimmune disorders or can occur as a paraneoplastic syndrome.

The primary treatments for autoimmune gastrointestinal dysmotility include medications, surgical interventions, dietary management, and physical therapy. Medications are used to manage AGID by reducing inflammation and improving digestive tract motility. Drug classes include prokinetic agents, anti-inflammatory drugs, immunosuppressive drugs, and antibiotics. Conditions associated with AGID include gastroparesis, chronic intestinal pseudo-obstruction (CIPO), functional dyspepsia, irritable bowel syndrome (IBS), and celiac disease. These medications are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels, and are utilized by hospitals, clinics, home care settings, and research institutions.

The autoimmune gastrointestinal dysmotility market consists of revenues earned by entities by providing services such as diagnostic testing, therapeutic treatments, clinical consultations, surgical interventions, rehabilitation and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The autoimmune gastrointestinal dysmotility market also includes sales of diagnostic kits, immunomodulatory drugs, prokinetic agents, and intravenous immunoglobulin (IVIG) therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.